NCT02676778 · OUTCOME
AUC(0-t ): Area Under the Serum Concentration-time Curve From Time 0 to the Last Measurable Point for E7777
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma · Source last updated 2021-07-15
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- nanogram*minute permilliliter(ng*min/mL)
- Interval / dispersion
- Standard Deviation
- Time frame
- Cycle 1 Day 1: 0-240 minutes post-infusion; Cycle 3 and 5 Day 1: 0-120 minutes post-infusion (each Cycle length = 3 weeks)
Analysis population: The PK analysis set was defined as a group of participants who received at least 1 dose of the study drug with at least 1 serum concentration data, and included participants who had been taken frequent blood sampling for non-compartment analysis. PK-evaluable population where data at specified time points was available.
Groups in this outcome
PTCL and CTCL Participants: E7777 9 mcg/kg/Day
Participants with relapsed or refractory PTCL and CTCL received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| PTCL and CTCL Participants: E7777 9 mcg/kg/Day | 11 |
|---|
Reported measurements
Cycle 1 Day 1
Analysis denominator · Participants
| Group | Source count |
|---|
| PTCL and CTCL Participants: E7777 9 mcg/kg/Day | 11 |
|---|
Values in nanogram*minute permilliliter(ng*min/mL) · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| PTCL and CTCL Participants: E7777 9 mcg/kg/Day | 17600 | 8040 | Not reported | Not reported | Not reported |
|---|
Cycle 3 Day 1
Analysis denominator · Participants
| Group | Source count |
|---|
| PTCL and CTCL Participants: E7777 9 mcg/kg/Day | 1 |
|---|
Values in nanogram*minute permilliliter(ng*min/mL) · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| PTCL and CTCL Participants: E7777 9 mcg/kg/Day | 15800 | NA | Not reported | Not reported | Standard deviation could not be calculated because only one participant was analysed. |
|---|
Cycle 5 Day 1
Analysis denominator · Participants
| Group | Source count |
|---|
| PTCL and CTCL Participants: E7777 9 mcg/kg/Day | 1 |
|---|
Values in nanogram*minute permilliliter(ng*min/mL) · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| PTCL and CTCL Participants: E7777 9 mcg/kg/Day | 16500 | NA | Not reported | Not reported | Standard deviation could not be calculated because only one participant was analysed. |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 8040
- value
- 17600
- title
- Cycle 1 Day 1
- categories
- measurements
- comment
- Standard deviation could not be calculated because only one participant was analysed.
- group Id
- OG000
- spread
- NA
- value
- 15800
- title
- Cycle 3 Day 1
- categories
- measurements
- comment
- Standard deviation could not be calculated because only one participant was analysed.
- group Id
- OG000
- spread
- NA
- value
- 16500
- title
- Cycle 5 Day 1
- dispersion Type
- Standard Deviation
- groups
- description
- Participants with relapsed or refractory PTCL and CTCL received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).
- id
- OG000
- title
- PTCL and CTCL Participants: E7777 9 mcg/kg/Day
- param Type
- MEAN
- population Description
- The PK analysis set was defined as a group of participants who received at least 1 dose of the study drug with at least 1 serum concentration data, and included participants who had been taken frequent blood sampling for non-compartment analysis. PK-evaluable population where data at specified time points was available.
- reporting Status
- POSTED
- time Frame
- Cycle 1 Day 1: 0-240 minutes post-infusion; Cycle 3 and 5 Day 1: 0-120 minutes post-infusion (each Cycle length = 3 weeks)
- title
- AUC(0-t ): Area Under the Serum Concentration-time Curve From Time 0 to the Last Measurable Point for E7777
- type
- SECONDARY
- unit Of Measure
- nanogram*minute permilliliter(ng*min/mL)
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice